What age or asthma groups should avoid FluMist, and why?

The short version: the official advice says children under 2 and those with asthma should avoid FluMist, but the evidence behind those rules is thin and the real question is whether the risk of a live virus in an inflamed airway outweighs any benefit.

The official US and UK contraindications for FluMist (live attenuated influenza vaccine, LAIV) are children under 2 years old and people with asthma or recurrent wheezing in children under 5. The reasoning is that a live virus replicating in the nose and throat of a very young child or someone with hyperreactive airways could trigger wheezing, asthma attacks, or even pneumonia. The evidence for this caution comes from a few small studies. One trial of just 48 children with moderate to severe asthma found no significant drop in lung function after LAIV, but the sample was tiny and the asthma exacerbation rate was 2 out of 24 in the vaccine group versus 0 out of 24 in the placebo group [11]. That difference was not statistically significant, but it is a signal that a larger study might have found. A larger safety study in healthy children aged 18 months to 4 years found a relative risk of asthma of 2.85 in the first year after LAIV, meaning those children were nearly three times more likely to have an asthma event than unvaccinated children [10]. That risk disappeared in later years, but it was real in the first year.

The age cut-off at 2 years is even less well studied. The same safety study in children 18 months to 4 years found no excess asthma in the second through fourth years, but the first-year risk was elevated [10]. The 2005 VAERS analysis covering about 2.5 million doses found 12 asthma-related reports, 5 of them serious, and noted that many of those occurred in people who should not have been vaccinated [16]. The problem is that the studies that exist compare vaccinated to vaccinated, or use passive surveillance that misses most events. The most informative design — a randomized trial of LAIV versus true placebo in children under 2 and in asthmatics, tracking hard outcomes like hospitalization and death — was never run. The burden of proof is on the intervention, and that proof is missing.

My call: the official age and asthma contraindications for FluMist are based on plausible mechanism and weak evidence, not on robust safety trials. The risk of a live virus in a child with inflamed airways is real but unquantified, and the benefit of flu prevention in that same child is also modest. The evidence does not support a blanket rule; it supports a case-by-case decision that most clinicians are not equipped to make because the data was never collected.

Confidence: moderate, because the mechanism is plausible and the few studies that exist point in the same direction, but the key trial (LAIV versus true placebo in asthmatic children with hard endpoints) was never done.